We were encouraged to see some very promising results from a Phase II clinical trial for high grade Neuroendocrine Carcinoma (NEC) patients, using a combination of Immunotherapy drugs. The results of this trial were recently presented at the American Association for Cancer Research Annual Meeting.
Click here for link to full press release
We welcome more research for these NEC patients and all NET Cancer patients and look forward to seeing more results based on real world experience.
NeuroEndocrine Cancer Australia (NECA) was proud to attend the 5th Neuroendocrine Tumour (NET) Preceptorship held 13 & 14th June at Peter MacCallum Cancer Centre in
NeuroEndocrine Cancer Australia at ENETS 2025: Advancing NET Care on the Global Stage NeuroEndocrine Cancer Australia (NECA) proudly represented Australia at the 22nd Annual European
Shaping the future of cancer control together We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year
